Dialysis industry news

Stories from the dialysis comunity across the globe.

Global Renal Dialysis market 2015 to grow at a CAGR of 4.59 percent over the ... - Medgadget.com (blog) PDF Print

The kidney is an important organ, which helps in maintaining the internal equilibrium of water and minerals. Renal dialysis is the process of the removing toxin substances such as creatinine and urea and excess amount of free water from the blood. Dialysis is a treatment used when in acute and chronic disturbance in the functioning of the kidney. Renal dialysis plays a major role in improving patients’ quality of life.

Global Renal Dialysis market to grow at a CAGR of 4.59 percent over the period 2013-2018.

Covered in this Report

The Global Renal Dialysis market can be segmented into the revenue generated from various products and services offered by vendors such as hemodialysis or peritoneal dialysis

Global Renal Dialysis Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Renal Dialysis market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Request For Sample Report Here:

Key Regions


Key Vendors

DaVita Healthcare
Fresenius Medical care

Other Prominent Vendors

Chongqing Shanwaishan
Diaverum Deutschland
Guangdong Biolight Meditech
Huaren Pharmaceutical
Jihua Medical
Medical Components
NxStage Medical
Sichuan Kelun Pharmaceutical

Market Driver

Growing ESRD Patient Population
For a full, detailed list, view our report

Market Challenge

Associated Risks and After-effects of Dialysis Treatment
For a full, detailed list, view our report

Market Trend

Expanding Economies in APAC Region
For a full, detailed list, view our report

Key Questions Answered in this Report

What will the market size be in 2018 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?


NT Health Minister John Elferink on death, dollars and dialysis - Crikey (registration) (blog) PDF Print

NT Health Minister John Elferink is one of those politicians who would have you believe that he is the smartest person in any room he’s in.

Sometimes his calls are crazy-brave, sometime they just seem more than a little crazy, or as NT News columnist Maria Billias said of his latest spray in The Daily Telegraph yesterday:

I am absolutely appalled that anyone–particularly the Health Minister of the Northern Territory–would think this is an acceptable thing to even think, let alone say. Unless of course they had a sociopathic personality disorder.

Billias was railing–in the very real-world context of her beloved 85-year-old grandfather’s battle with dementia–against Elferink’s comments made yesterday that because the elderly and chronically ill consume a disproportionate part of the NT health budget, particularly in the last years of their life, that that money would be better spent on the young.

Elferink used kidney disease as an example of where such savings might be made.

I suspect if you spoke to somebody who … for argument’s sake, had end-stage renal failure and said, ‘we can continue treatment but by discontinuing treatment your grandchildren would have a better opportunity’, many of those old people would say ‘yeah, I accept that.’

Elferink was speaking to the ABC after the annual Australasian Aeromedical Conference in Darwin and told the ABC that he had talked to other Government ministers about the idea but was yet to form a “concrete policy.” Elferink–ever ready to give the personal responsibility drum a solid flogging–has apparently been thinking about the strains that treating the chronically ill and aged place on the NT health budget for a while.

In June this year Elferink told an NT Estimates hearing that, in relation to how Federal funding cuts had effected–among other things–the delivery of renal dialysis services across the NT:

We continue to provide as many renal dialysis services as we can … The capacity will eventually reach a threshold where there is only so much we can deliver. Then what? This is why I am trying to change the conversation about where the responsibility lies. I understand there are those issues, but the fact is this expectation that the government will wave a magic wand and look after your kidney failure is something we will attend to, but we cannot do it indefinitely to a point where we spend the whole Territory budget on it – or more.

This is a challenge for us, and I seek to see improvements in people’s behaviour. So much of what comes through the health system in the Northern Territory and in other places around the world is often the response to bad decisions by the people who get themselves into those chronic phases.

That last comment about the causes of kidney failure, as with Elferink’s comments yesterday that an elderly person with a terminal illness costs the NT health system about $1 million per year, appears unsupported by any evidence.

You could be forgiven for thinking that Elferink has a fixation with death and dying. Just last week, in response to a coronial report into a death in custody and wearing his Attoney-General’s hat Elferink said that Kumunjayi Langdon “would have died a free man in the gutter.”

The Northern Myth thought it might be useful to ask someone who knows about the delivery of dialysis services in remote parts of the NT. Sarah Brown works at The Purple House, (aka Western Desert Dialysis) an NGO that provides dialysis services to remote NT communities and has a mission statement of blinding clarity and simplicity:

… to improve the lives of people with renal failure, reunite families and reduce the incidence of kidney disease in our communities.

The Northern Myth asked Sarah Brown if she could elaborate on the causes of kidney disease. She said of Elferink’s comments that they were typical of the sort of “blaming the victim crap” that was unfortunately all too often spouted by politicians and the ill-informed and that:

The causes of renal failure are complex. But what we do know is that the highest rates of kidney disease are found in fourth-world communities. This is the situation we face in central and remote Australia. Renal failure is a post-colonial disease, short and simple.

To be fair to Elferink there is a small grain of common sense in his call for a re-allocation of stretched funds from those that take the most for the least return to those who need, or would benefit from, more resources. But Elferink delivers his message in such a clumsy faux-neoliberal manner that any reason in his message is lost in the outrage it sparks.

As Sarah Brown notes, Elferink’s comments, particularly that many of the elderly might willingly surrender a benefit to themselves for the greater good of the young, poses what would be for many remote Aboriginal people a very difficult question.

You’d be asking people to choose between taking care of their old people and taking care of their kids.

For mine the real problem with Elferink’s comments is that they contain an implicit assumption that renal failure and dialysis treatment delay the inevitable stagger towards an expensive and miserable death and that treatment contributes little toward community well-being and individual quality of life.

Earlier this month the Purple House took their Purple Bus (which has two portable dialysis chairs) to the Yuendumu Sports weekend, 300 kilometres north-west of Alice Springs.

Sarah Brown again:

At Yuendumu there are four dialysis chairs in a stand-alone centre next to the health clinic. We took the Purple Bus up for the weekend and more than twenty patients came up who were dialysing on six machines all day and half of the night. This is what really matters about our work, taking people who would normally be stuck in Alice Springs–miserable and homesick–back to their country so they can see all the young babies  and kids and the kids can see their grannies and family again. It was such a great thing. This is what our politicians miss–it doesn’t have to be about the elderly and sick and the young and well and taking from one to give to the other. If you do it right the whole community can benefit.

A few weeks ago The Purple House received some very good news of increased funding from the Federal Government that will see their services rolled out to even more remote NT townships. But they need more dialysis nurses to work with them, so they’ve taken an innovative approach to recruitment.

… as an added incentive, we will pay a SPOTTERS FEE of $500 to the person who introduces them to us. We’d rather pay our friends than an agency, so mates…get to it! Email us at This e-mail address is being protected from spambots. You need JavaScript enabled to view it for more details or give Deb or Morgan a call on (08) 89536444.


3 Stocks Pushing The Health Services Industry Lower - TheStreet.com PDF Print

3 Stocks Pushing The Health Services Industry Lower
KGaA, a kidney dialysis company, provides dialysis care services related to the dialysis treatment a patient receives with end stage renal disease (ESRD); and other health care services. Fresenius Medical Care AG & Co. KGaA has a market cap of $25.5 ...

and more »


Today's Roof Leaker Stock Is DaVita HealthCare Partners (DVA) - TheStreet.com PDF Print
DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates in two divisions, Kidney Care and HealthCare Partners. DVA has a PE ratio of 39.
DaVita HealthCare Partners Director Sells $322757.34 in Stock (DVA) Dakota Financial News
Inside Trading: Carol Davidson Unloaded 4038 Shares of DaVita HealthCare ... OctaFinance.com
Davita Healthcare Partners Inc. (DVA) Files Form 4 Insider Selling : Carol


Nxstage Medical, Inc. (NXTM) Discloses Form 4 Insider Selling : Exec. Winifred ... - American Trade Journal PDF Print

Nxstage Medical, Inc. (NXTM) Discloses Insider Transaction. Winifred L Swan , SVP and General Counsel of Nxstage Medical, Inc. sold 2,500 shares on Aug 14, 2015. The Insider selling transaction was disclosed on Aug 17, 2015 to the Securities and Exchange Commission. The shares were sold at $18.14 per share for a total value of $45,350.00.

The company shares have rallied 37.01% in the past 52 Weeks. On April 27, 2015 The shares registered one year high of $19.63 and one year low was seen on September 16, 2014 at $11.5. The 50-day moving average is $15.12 and the 200 day moving average is recorded at $16.65. S&P 500 has rallied 6.63% during the last 52-weeks. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the (President) of Nxstage Medical, Inc., Turk Joseph E Jr had sold 3,252 shares worth of $57,690 in a transaction dated August 12, 2015. In this transaction, 3,252 shares were sold at $17.74 per share. Wall Street Brokerage Firms have recommended on the company shares. 5 analysts have rated the shares as a strong buy. The Company shares has received a rating of Buy from 1 Wall Street Analysts. 1 analysts have rated Hold. A Sell call was given by 1 analyst. NxStage Medical, Inc. (NASDAQ:NXTM) should head towards $21 per share according to 4 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $15 per share. The higher price estimate target is at $24 according to the Analysts. Shares of NxStage Medical, Inc. (NASDAQ:NXTM) ended Tuesday session in red amid volatile trading. The shares closed down 0.17 points or 0.93% at $18.19 with 399,924 shares getting traded. Post opening the session at $18.28, the shares hit an intraday low of $18.09 and an intraday high of $18.47 and the price vacillated in this range throughout the day. The company has a market cap of $1,154 million and the number of outstanding shares has been calculated to be 63,448,000 shares. The 52-week high of NxStage Medical, Inc. (NASDAQ:NXTM) is $19.63 and the 52-week low is $11.5. NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market.


<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 6 of 4210
Share |
Copyright © 2018 Global Dialysis. All Rights Reserved.